Sharemaestro company-news research for CG Oncology, Inc. Common stock (CGON), showing current tone, evidence confidence, direct company coverage, sector and industry context, completed price response and the source headlines used on the page. Scores describe published news evidence. Confidence describes the amount, freshness, source breadth and direct company relevance of that evidence. Price context is shown separately.
NASDAQ
United States
Provisional evidence
Company news sentiment
Latest CGON news and sentiment
CG Oncology, Inc. Common stock
Company headlines from the last 30 days, weighted by freshness, relevance, publisher quality and the strength of the wording. Price is shown separately.
30-day score50Neutral is 50
Early balanced news score
19/100 evidence confidence
100% direct company focus
12 current stories across 3 publishers
Current company news
Early balanced news score
12 company-specific stories are available, but there are not yet enough fresh stories from separate publishers for a firm reading.
Observed headline tone44/100
→
Published 30-day score50/100
Latest source headline
After $7.9M sale, CG Oncology (NASDAQ: CGON) officer plans more stock trades
Stock Titan · 22 Sep 2026 05:57
Older, less relevant and less reliable stories count for less. Confidence is shown separately.
What supports the score
12 current stories are mapped specifically to CGON.
The score uses 3 publishers rather than depending on one outlet.
What limits the score
The stories agree, but freshness-weighted evidence is only 0.061.
Confidence is 19/100, below the threshold for a firm score.
50/100
News scoreEarly balanced news score
19/100
Confidencethin evidence
100%/100
Company news12 company stories
95/100
Story agreement5/100 difference
News history
Daily score and story count over 30 days
27 Aug11 Sep25 Sep
News scoreStory count50 baseline
Confidence
How reliable the score is
Confidence uses the amount of news, separate publishers, direct company relevance, freshness and agreement. A high or low score is not automatically reliable.
Amount of evidence1
0.061 after freshness weightingSource breadth60
3 independent publishersCompany relevance100
share tied directly to this companyFreshness23
recency-weighted evidenceAgreement95
how closely stories agreePublisher mix51
less reliance on one publisherPrice and news history
Weekly price and news-score history
Company-specific news is present, but the evidence has not yet earned enough independent, fresh information weight for price confirmation to be treated as a firm signal.
26 completed price weeks13 comparable news-score weeks
One scoring method across the chart.Stored company headlines are recalculated at each weekly point with the current 30-day freshness weighting. Old published snapshots are left unchanged.
27 Mar23 Jun18 Sep
Weekly close, indexedSentiment score
WeekNews scoreCloseWeekly move
18 Sep 202648USD 74.62+3.1%
11 Sep 202650USD 72.35-3.1%
04 Sep 202649USD 74.67+0.4%
28 Aug 202648USD 74.34-6.9%
21 Aug 202648USD 79.81+6.4%
14 Aug 202650USD 75.03-0.1%
07 Aug 202645USD 75.1+5.5%
31 Jul 202650USD 71.19+2.7%
Provisional evidence
News subjects
What is shaping the score
Market update466 stories · 50%
Earnings475 stories · 42%
Analyst action421 stories · 8%
Source mix
Where the evidence comes from
Stock Titan464 stories · 33%
MarketBeat543 stories · 25%
careplusvn.com431 stories · 8%
Simply Wall St.551 stories · 8%
Investing.com India501 stories · 8%
GlobeNewswire501 stories · 8%
SFGATE501 stories · 8%
Recurring subjects
Subjects appearing most often
Life Sciences9Financial Markets5Finance5Earnings4Biotech2Valuation1Shareholder1Share Price1Real Estate1IPO1
Earlier readings
How the score has changed
Past and present use the same method.Each point recalculates the previous 30 days of stored company headlines with today's scoring rules. The original stored snapshots remain unchanged.
22 Jun50 neutral25 Sep 11:25
ConstructiveBalanced or withheldCautious
Changes in the stored score
Scores are rebuilt from stored headlines with the current 30-day method. Days with no change are collapsed.
| Observed | Score | Move | Confidence | Stories | Status |
|---|---|---|---|---|---|
| 25 Sep 11:25 | 50 | +1 | 19/100 (-2) | 12 (-1) | Provisional |
| 22 Sep 23:59 | 49 | +1 | 21/100 (-8) | 13 (-1) | Provisional |
| 18 Sep 23:59 | 48 | -1 | 29/100 (-1) | 14 (-3) | Provisional |
| 17 Sep 23:59 | 49 | -1 | 30/100 (+12) | 17 (-9) | Provisional |
| 10 Sep 23:59 | 50 | +0 | 18/100 (-1) | 26 (-1) | Provisional |
| 09 Sep 23:59 | 50 | +1 | 19/100 (-5) | 27 (-23) | Provisional |
| 03 Sep 23:59 | 49 | +0 | 24/100 (-2) | 50 (0) | Provisional |
| 02 Sep 23:59 | 49 | +0 | 26/100 (-4) | 50 (0) | Provisional |
Source headlines
The news behind the score
Only company-specific stories enter this score. The latest 30 days are shown newest first, with newer stories weighted more heavily and duplicate coverage combined.
#1—Not directional
Stock TitanDirect company coverageStored article
After $7.9M sale, CG Oncology (NASDAQ: CGON) officer plans more stock trades
CG Oncology (NASDAQ: CGON) officer Ambaw Bellete has filed a Rule 144 notice indicating an intended sale of 30,787 shares of common stock, tied to a stock option exercise, with Morgan Stanley Smith Barney LLC handling the transaction on NASDAQ. The filing also reveals numerous prior sales by Bellete over the past three months, including a significant sale of 100,000 shares on August 19, 2026, valued at over $7.9 million. These transactions highlight insider activity and potential market impact for CGON investors.
FinanceLife Sciences
- Published
- 22 Sep 2026 05:57
- News subject
- Market update
- Why this score
- The headline reports news without a clear direction
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 3.2d old
- Duplicates
- 2 consolidated
#240Tone
Stock TitanDirect company coverageStored article
CG Oncology (NASDAQ: CGON) officer sold 100,000 shares and now plans more
An officer at CG Oncology (CGON), Ambaw Bellete, has filed a Rule 144 notice to sell 6,532 shares of common stock, valued at approximately $499,698, after previously selling 100,000 shares for over $7.9 million on August 19, 2026. The filing indicates a stock option exercise and multiple other significant sales by Bellete in the past three months, alongside the company's reported 88,640,375 shares outstanding. This proposed sale will be executed through Morgan Stanley Smith Barney.
FinanceFinancial MarketsLife Sciences
- Published
- 18 Sep 2026 05:57
- News subject
- Market update
- Why this score
- Institutional or insider selling
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Story strength
- Medium · 38/100
- 30-day weight
- 17.3% of the score · 7.2d old
- Duplicates
- 2 consolidated
#342Tone
Stock TitanDirect company coverageStored article
CG Oncology (NASDAQ: CGON) director sells shares under preset trading plan
CG Oncology director Leonard E. Post exercised options for 1,000 shares and simultaneously sold them at a weighted average price of $72.98 under a pre-arranged Rule 10b5-1 trading plan. The transaction resulted in an approximate pre-tax spread of $72,000. Following these transactions, Post directly held 103,077 option-based rights.
FinanceLife Sciences
- Published
- 17 Sep 2026 20:30
- News subject
- Market update
- Why this score
- Institutional or insider selling
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Story strength
- Low · 33/100
- 30-day weight
- 10.4% of the score · 7.6d old
- Duplicates
- 2 consolidated
#443Tone
careplusvn.comDirect company coverageScored from headline
CGON Q2 2026 Earnings: Wider-Than-Expected Loss as Clinical-Stage Costs Weigh on Results
- Published
- 17 Sep 2026 16:44
- News subject
- Earnings
- Why this score
- Negative financial language
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Story strength
- Medium · 41/100
- 30-day weight
- 63.7% of the score · 7.8d old
- Duplicates
- 2 consolidated
#5—Not directional
Investing.com IndiaDirect company coverageStored article
CG Oncology at Cantor conference: cretostimogene nears key readout
CG Oncology discussed its lead drug, cretostimogene, for non-muscle invasive bladder cancer (NMIBC) at the 12th Annual Cantor Fitzgerald Global Healthcare Conference. The company is nearing a key Phase III readout for intermediate-risk NMIBC, advancing manufacturing for its initial BLA, and planning a third Phase III trial for BCG-exposed high-risk disease. Despite strong clinical progress, the company acknowledges market competition and the need to demonstrate real-world adoption, with financial profitability not expected until after 2026.
EarningsFinancial MarketsLife Sciences
- Published
- 10 Sep 2026 15:37
- News subject
- Earnings
- Why this score
- Positive financial language
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 14.8d old
- Duplicates
- 1 consolidated
#6—Not directional
Stock TitanDirect company coverageStored article
Planned CG Oncology (NASDAQ: CGON) insider sale totals 826 shares
An officer at CG Oncology (NASDAQ: CGON), Ambaw Bellete, plans to sell 826 shares of common stock for $61,950 on September 11, 2026, following a stock option exercise. This information comes from a Rule 144 SEC filing. The filing also details numerous prior sales by Bellete over the preceding three months, including a 100,000-share sale for over $7.9 million on August 19, 2026.
FinanceLife Sciences
- Published
- 09 Sep 2026 19:47
- News subject
- Market update
- Why this score
- Institutional or insider selling
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 15.7d old
- Duplicates
- 2 consolidated
#7—Not directional
Simply Wall St.Direct company coverageStored article
CG Oncology (CGON) Stock Looks Fully Priced After A 160% Run
CG Oncology stock has delivered very strong 1 year gains, yet the broader valuation checks and current pricing leave investors weighing how much of the story is already reflected in the share price. The stock is up 160.2% over the past year, which means anyone buying today is doing so after a very sharp re rating rather than early in the move. Expectations for CG Oncology to turn its pipeline into durable revenue can support the current valuation, while execution risk around clinical progress and eventual commercialization may constrain how much investors are willing to pay. The overall value
BiotechClinical TrialsShare PriceShareholderValuation
- Published
- 03 Sep 2026 13:06
- News subject
- Earnings
- Why this score
- Positive financial language
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 21.9d old
- Duplicates
- 3 consolidated
#8—Not directional
GlobeNewswireDirect company coverageStored article
CG Oncology to Present at Upcoming Investor Conferences in September
CG Oncology Inc. DALLAS, Sept. 02, 2026 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON) today announced that Arthur Kuan, Chairman, President & Chief Executive Officer, will participate in fireside chat presentations at the Cantor Fitzgerald and Morgan Stanley Global Healthcare Conferences in New York City this month. The details of the upcoming events are as follows: Cantor Fitzgerald Global Healthcare Conference Presentation Time: Wednesday, September 9, 2026 at 8:00am ET Morgan Stanley Global Healthcare Conference Presentation Time: Monday, September 14, 2026 at 4:50pm ET Interested pa
BiotechConferencesHealthcare
- Published
- 02 Sep 2026 12:00
- News subject
- Market update
- Why this score
- The headline reports news without a clear direction
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 23.0d old
- Duplicates
- 1 consolidated
#942Tone
MarketBeatDirect company coverageStored article
CG Oncology, Inc. $CGON Shares Sold by Wellington Management Group LLP
Wellington Management Group LLP reduced its stake in CG Oncology (NASDAQ:CGON) by 0.9% in Q2 2026, selling 46,481 shares but still holding 5.32 million shares worth $378.3 million. Analyst sentiment for CGON is largely positive, with a "Moderate Buy" consensus and an average price target of $83.18. The company reported a Q2 loss of $0.90 per share, missing estimates, but revenue exceeded expectations.
EarningsFinancial MarketsLife Sciences
- Published
- 31 Aug 2026 18:31
- News subject
- Analyst action
- Why this score
- Institutional or insider selling
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Story strength
- Low · 31/100
- 30-day weight
- 0.7% of the score · 24.7d old
- Duplicates
- 1 consolidated
#10—Not directional
SFGATEDirect company coverageStored article
California loses another multibillion-dollar company to Texas
Biotech company CG Oncology, valued at $7 billion, has moved its headquarters from Irvine, California, to Dallas, Texas, signing an eight-year lease at Pegasus Park. The company, which focuses on bladder cancer immunotherapy, cited better access to talent and new facilities as reasons for the relocation. This move follows a trend of other California-headquartered companies relocating to Texas.
Economy MacroLife SciencesReal Estate
- Published
- 31 Aug 2026 04:23
- News subject
- Market update
- Why this score
- The headline reports news without a clear direction
- Company focus
- Company discussed · 86%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 25.3d old
- Duplicates
- 1 consolidated
#1160Tone
MarketBeatDirect company coverageStored article
CG Oncology, Inc. $CGON Shares Purchased by Algert Global LLC
Algert Global LLC significantly increased its stake in CG Oncology, Inc. (NASDAQ:CGON) by 140.9% in the second quarter, bringing its total to 46,690 shares valued at approximately $3.3 million. The article also details mixed insider activity, including a major director purchase and sales, and notes that institutional investors collectively own 26.56% of the company. Despite missing analyst EPS estimates for the last quarter, CG Oncology's revenue exceeded forecasts, and analysts maintain a "Moderate Buy" consensus rating with an $83.18 price target.
EarningsFinancial MarketsLife Sciences
- Published
- 29 Aug 2026 17:51
- News subject
- Earnings
- Why this score
- Institutional or insider buying
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Story strength
- Medium · 37/100
- 30-day weight
- 8% of the score · 26.7d old
- Duplicates
- 1 consolidated
#12—Not directional
MarketBeatDirect company coverageStored article
ADAR1 Capital Management LLC Invests $8.43 Million in CG Oncology, Inc. $CGON
ADAR1 Capital Management LLC has acquired 118,664 shares of CG Oncology, Inc. (NASDAQ:CGON) for approximately $8.43 million, establishing a new position in the clinical-stage biopharmaceutical company. Despite this institutional investment and a "Moderate Buy" consensus rating from analysts, CG Oncology recently missed its quarterly earnings expectations. The company's stock opened at $78.95, near its 52-week high, with institutional investors collectively owning 26.56% of the shares.
EarningsFinanceFinancial MarketsIPOLife Sciences
- Published
- 26 Aug 2026 17:51
- News subject
- Earnings
- Why this score
- Missed expectations
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 29.7d old
- Duplicates
- 1 consolidated
Earlier company news
CGON news archive
Stored newest first for historical research. It starts after the newest three pages above and then continues through older news. Each archive page is loaded only when it is opened.
Older news is kept in the archive
There are 104 older CGON headlines. Open one page at a time when you need them.
Open older archiveProvider matches checked
Provider mentions not used in the score
A news provider linked these stories to CGON, but the headline and available text are not mainly about CG Oncology, Inc. Common stock. They are kept here for transparency and do not affect the score, confidence, history or wider market totals.
Provider mentions are kept separate
Open the list to see which provider matches were checked and left out of CGON sentiment.
Open provider mentionsHow the page works
How to read the score
It describes the weighted balance of qualifying headlines. A score of 50 can mean balanced news or that there is not enough evidence; the status label explains which.
Confidence measures depth, source breadth, direct relevance, freshness and agreement. It does not rise merely because the tone is extreme.
Weekly price response, trend and fair-value position test whether the market is accepting or rejecting the news. They never rewrite the news score.
It measures news already published. It is not a forecast, recommendation or price target.